HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[TNF-alpha blocking therapy in chronic inflammatory bowel disease].

Abstract
The introduction of TNF-alpha blocking therapy has produced a dramatic change in the treatment of therapy resistant patients with inflammatory bowel disease. Both infliximab and adalimumab are effective in moderately severe and severe Crohn's disease. Besides, infliximab is potent in the remission and its sustaining in ulcerative colitis. However, among therapy resistant individuals, 20-30 percents of patients with Crohn's disease and 30-40 percents of patients with ulcerative colitis do not respond to these treatments. To date, no comparative study between the two drugs has been carried out and the clinical trials can not be directly compared to each others, still, on the basis of general considerations, there is no essential difference in the effectiveness between the two treatments.
AuthorsTamás Molnár
JournalOrvosi hetilap (Orv Hetil) Vol. 150 Issue 38 Pg. 1773-9 (Sep 20 2009) ISSN: 0030-6002 [Print] Hungary
Vernacular TitleTNF-alpha-blokkoló kezelés krónikus, ismeretlen eredetu gyulladásos bélbetegségekben.
PMID19740722 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin Fab Fragments
  • Tumor Necrosis Factor-alpha
  • Polyethylene Glycols
  • Infliximab
  • Adalimumab
  • Certolizumab Pegol
Topics
  • Adalimumab
  • Anti-Inflammatory Agents (pharmacology, therapeutic use)
  • Antibodies, Monoclonal (pharmacology, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Certolizumab Pegol
  • Chronic Disease
  • Colitis, Ulcerative (drug therapy)
  • Crohn Disease (drug therapy)
  • Humans
  • Immunoglobulin Fab Fragments (pharmacology, therapeutic use)
  • Inflammatory Bowel Diseases (drug therapy, metabolism)
  • Infliximab
  • Polyethylene Glycols (pharmacology, therapeutic use)
  • Severity of Illness Index
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: